929118-36-5

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-[1-[3-[2-[4-(1-methylethoxy)phenoxy]-5-thiazolyl]-5-isoxazolyl]ethyl]-
• CAS NO: 929118-36-5
• Molecular Formula: C25H21N3O5S
• Molecular Weight: 475.525
• Mol File: 929118-36-5.mol

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-[1-[3-[2-[4-(1-methylethoxy)phenoxy]-5-thiazolyl]-5-isoxazolyl]ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-[1-[3-[2-[4-(1-methylethoxy)phenoxy]-5-thiazolyl]-5-isoxazolyl]ethyl]-(929118-36-5)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-[1-[3-[2-[4-(1-methylethoxy)phenoxy]-5-thiazolyl]-5-isoxazolyl]ethyl]-(929118-36-5)

Safety Data

• Hazardous Substances Data: 929118-36-5(Hazardous Substances Data)

Usage

Molecular structure

1H-Isoindole-1,3(2H)-dione core with additional side chains and rings.

Side chains

1-methylethoxyphenoxy and ethyl side chains.

Heterocyclic rings

Thiazole and isoxazole rings.

Complex chemical compound

Contains diverse functional groups.

Potential pharmacological properties

Activity on enzymes, receptors, or ion channels.

Biological activity

Requires further studies for full understanding.

Potential applications

Unclear, but may have various uses due to its complex structure and pharmacological properties.

Upstream product

• 929118-31-0 N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride 
• 14396-89-5 2-(1-methylprop-2-ynyl)-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-CoA carboxylase inhibitors - Improvement of cardiovascular and neurological liabilities via structural modifications

A preliminary safety evaluation of ACC2 inhibitor 1-(S) revealed serious neurological and cardiovascular liabilities of this chemotype. A systematic structure-toxicity relationship study identified the alkyne linker as the key motif responsible for these adverse effects. Toxicogenomic studies in rats showed that 1-(R) and 1-(S) induced gene expression patterns similar to that seen with several known cardiotoxic agents such as doxorubicin. Replacement of the alkyne with alternative linker groups led to a new series of ACC inhibitors with drastically improved cardiovascular and neurological profiles.

NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME

The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.